MCIM
DNTH icon

Meadow Creek Investment Management’s Dianthus Therapeutics DNTH Stock Holding History

Meadow Creek Investment Management’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$22K Hold
133
– – ﹤0.01% 1314
2019
Q2 		$31K Hold
133
– – ﹤0.01% 1307
2019
Q1 		$35K Hold
133
– – ﹤0.01% 1287
2018
Q4 		$12K Sell
133
-109
-45% -$14.9K ﹤0.01% 1294
2018
Q3 		$46K Hold
242
– – ﹤0.01% 1273
2018
Q2 		$52K Buy
+242
New +$54.6K ﹤0.01% 1249

Other funds holding DNTH

TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return

Meadow Creek Investment Management's DNTH Position: Q3 2019 in Review

Meadow Creek Investment Management held its Dianthus Therapeutics (DNTH) position steady in Q3 2019 at 133 shares worth $22K. The position accounts for ﹤0.01% of the portfolio, ranked #1314.

Meadow Creek Investment Management first reported a position in DNTH in Q2 2018 and has held it in 6 quarters since. The position peaked at $52K in Q2 2018. 72 funds tracked by Wall St. Rank hold DNTH as of Q3 2019.

  • Meadow Creek Investment Management held 133 shares of Dianthus Therapeutics worth $22K as of Q3 2019.
  • Meadow Creek Investment Management left its Dianthus Therapeutics share count unchanged in Q3 2019.
  • Dianthus Therapeutics made up ﹤0.01% of Meadow Creek Investment Management's portfolio in Q3 2019, its #1314 holding.
  • Meadow Creek Investment Management first reported a position in Dianthus Therapeutics in Q2 2018 and has held it in 6 quarters since.
  • Meadow Creek Investment Management's Dianthus Therapeutics position peaked at $52K in Q2 2018.
  • 72 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2019.

Based on Meadow Creek Investment Management's 13F filing for Q3 2019, filed 14 Nov 2019.